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1. Introduction 
“Bacterial infections are becoming increasingly resistant to existing antibiotics, and as the 
number of patients who have succumbed to these infections rises, the number of new 
antibiotics being developed continues to plummet.” This extract from a letter addressed to 
President Barack Obama by the president of Infectious Diseases Society of America 
(IDSA) attests to the urgent need for new therapeutic options to fight multidrug-resistant 
(MDR) bacteria. Drug-resistant infections and related morbidity and mortality are on the 
rise in the United States and around the world. Despite the growing antibiotic resistance 
among Gram-positive and Gram-negative pathogens causing severe infections in hospital 
and community settings, the number of new antibacterial drugs approved for marketing 
in the United States continues to decrease. In addition to this worrying situation, only a 
few novel therapeutics for drug-resistant infections are in the drug development pipeline 
(Boucher et al., 2009; European Centre for Disease Prevention and Control, 2009). Reports 
of bacterial isolates resistant to almost all available antibiotics highlight the crucial need 
for new antibiotic therapies, especially for Gram-negative infections (Maltezou, 2009). 
Recently, IDSA and United States authorities have developed creative incentives to 
stimulate new antibacterial research and development (Infectious Diseases Society of 
America, 2010).  
In vivo assessment is recognized as an essential link between in vitro data such as 
susceptibility testing and clinical studies. As indicated in 1999 in the introduction to the 
Handbook of Animal Models of Infection (Zak et al., 1999), it is hardly conceivable that a 
new antibiotic could move into clinical use without thorough verification of its antimicrobial 
efficacy in animal models of infection at an early stage. To facilitate the extrapolation of 
animal model data to humans, especially for determination of efficacy, animal models 
mimicking human disease are required. Pharmacokinetic (PK) and pharmacodynamic (PD) 
features of new antibacterial agents must be considered and differences between PK of 
antibiotics in animals and human should be limited using methods for obtaining human-like 
PK profiles in animals. Animal models mimicking human infections are considered 
discriminative models and are designed to assess the potent therapeutic effects of antibiotics 
against pathogens, and in some cases to extend or delimit the indications advisable for 
humans.  
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Animal models of endocarditis are used extensively to test the in vivo activities of new 
drugs or new regimens, and are particularly suitable for PK and PD analysis and 
optimization of therapeutic efficacy. Experimental endocarditis studies played a major role 
in the exploration and assessment of new antistaphylococcal drugs beginning with the 
oxazolidinone, linezolid, in the early 2000s, and were critical to the recent approval of the 
promising anti-MRSA cephalosporin ceftaroline by the United States Food and Drug 
Administration (FDA). The endocarditis model is referenced in approximately 100 PubMed 
publications, most of which are assessments of the in vivo activity of new therapeutic 
options against Staphylococcus aureus such as linezolid (Jacqueline et al., 2002), quinupristin-
dalfopristin (Batard et al., 2002), moxifloxacin (Entenza et al., 2001), daptomycin (Sakoulas et 
al., 2003), tigecycline (Murphy et al., 2000; Jacqueline et al., 2011), ceftobiprole (Tattevin et 
al., 2010) and ceftaroline (Jacqueline et al., 2007). Staphylococcus aureus is the most common 
cause of endocarditis worldwide and methicillin-susceptible Staphylococcus aureus (MSSA) is 
detected in up to two-thirds of cases (Fowler et al., 2005). High rates of clinical failure have 
been reported with vancomycin therapy for MRSA endocarditis. The emergence of 
glycopeptide-intermediate Staphylococcus aureus (GISA) strains further highlights the need 
for new therapeutic options for treatment of infections by S. aureus strains that are resistant 
to methicillin and glycopeptides.   
Ideally, clinicians should be able to use clinical trial data to support evidence-based 
medicine for the treatment of infectious diseases. However, difficulty in performing clinical 
trials in severe types of infection such as endocarditis has resulted in a lack of clinical 
information regarding use of new antibiotics in treating severe infections. Experimental 
animal models are one method used to assess the in vivo activity of new antimicrobials in 
the treatment of severe infections. 
2. Experimental model of endocarditis: How to? 
Although experimental rodent endocarditis models are sometimes used, white New 
Zealand female (weighing 2-2.5 kg) are most commonly used in experimental studies 
involving evaluation of antimicrobial agents. This model is based on the description by 
Garrison and Freedman in 1970 (Garrison & Freedman, 1970) modified by Durack and 
Beeson in 1972 (Durack & Beeson, 1972).  
The rabbit model, as currently used, is based on the insertion of a polyethylene catheter via 
the right carotid artery into the left ventricle under general anaesthesia. The catheter is left 
in place throughout the experiment (until the euthanasia of the animal). After catherization 
for 24 hours, each animal is inoculated i.v. (using the marginal ear vein) with 1 mL of a 
bacterial suspension of the test pathogen. The inoculum is usually prepared from an 
overnight culture (broth), centrifuged and calibrated in saline to the appropriate dilution 
(range, 105 to 109 CFU/mL).  Bacterial concentration of the inoculum (CFUs) is controlled by 
quantitative culture. Then, animals are randomly assigned to the different therapeutic 
regimens, including a control group (infected, no drug). The treatment is usually initiated 18 
to 24 hours after bacterial challenge given that the time between i.v. inoculation of the 
bacteria and start of antimicrobial therapy is critical. As observed in other animal 
experimental models, this factor can influence the efficacy of tested drugs. Administration of 
antibiotics is widely realized by the intramuscular (thigh) or i.v. (marginal ear vein) routes.  
The animals are euthanized by using an i.v. bolus of thiopental at the beginning of the 
treatment period (controls) or at the end of therapeutic regimen (range, 1 to 5 days). Aortic 
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valve vegetations are excised; immediately placed on ice; and then weighed, homogenized 
in saline buffer, and plated on agar plates for surviving bacteria counts. Dilutions are used 
to eliminate potential carryover. Viable counts after 24 h to 48 h of incubation at 37°C are 
expressed as the mean ± standard deviation log10CFU per gram of vegetation (most reliable 
judgement criteria). To determine whether antibiotic regimens could induce the selection of 
in vivo resistant variants, undiluted vegetation homogenates are spread on agar plates 
containing antibiotic at concentrations corresponding to two- and fourfold the MIC.  
The experimental model of endocarditis has demonstrated to be highly valuable in assessing 
in vivo efficacy of antimicrobial agents by providing endpoints relevant in the evaluation of 
antibiotics (Lefort & Fantin, 1999):  
- Surviving bacteria (expressed as number of CFU per gram of vegetation) 
- Blood cultures (positive/negative) 
- Ease of removing blood samples (PK assessment)  
- Detection of the emergence of resistant variants during therapy 
- Mortality 
- Incidence of relapse after therapy discontinuation. 
3. Linezolid, the first drug issued from the oxazolidinones, a novel class of 
synthetic antimicrobials 
First marketed as oxazolidinone in the early 2000’s, linezolid was approved by the United 
States FDA for the treatment of adults with nosocomial pneumonia, infections due to 
vancomycin-resistant Enterococcus faecium, complicated and uncomplicated skin and skin-
structure infections, and community-acquired pneumonia (Zyvox [package insert], 2000). 
This new drug was considered a promising new option against MRSA in a context of 
increasing numbers of infections caused by resistant gram-positive bacteria and the 
emergence of MRSA strains with reduced susceptibility to glycopeptides (Hiramatsu et al., 
1997).  
3.1 In vitro antibacterial activity of linezolid alone and in combination with other 
antibacterial agents 
Oxazolidinones are bacterial protein synthesis inhibitors: linezolid binds to a site on the 
bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 
70S initiation complex (Aoki et al., 2002). This mechanism of action is specific to this class, 
and no cross-resistance with other antimicrobial agents has been observed. As with most 
protein synthesis inhibitors, linezolid displays nonbactericidal, time-dependent activity in 
vitro against staphylococci (Kaatz & Seo, 1996) (Figure 1). The bacteriostatic and time-
dependent activity did not work in linezolid’s favor for clinical use, especially for treatment 
of severe infections, where most clinicians are convinced that bactericidal drugs are 
required. Consequently, many studies examined the in vitro activity of linezolid in 
combination with partner drugs (Table 1), including vancomycin (Grohs et al., 2003; 
Jacqueline et al., 2003; Soriano et al., 2005; Sahuquillo Arce et al., 2006; Singh et al., 2009), 
gentamicin (Grohs et al., 2003; Jacqueline et al., 2003), rifampicin (Grohs et al., 2003; 
Jacqueline et al., 2003; Soriano et al., 2005; Sahuquillo Arce et al., 2006), carbapenems 
(Jacqueline, 2005, 2006), fosfomycin (Sahuquillo Arce et al., 2006), doxycycline (Sahuquillo 
Arce et al., 2006), ciprofloxacin (Grohs et al., 2003), levofloxacin (Soriano et al., 2005; 
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Sahuquillo Arce et al., 2006), and fusidic acid (Grohs et al., 2003). Although indifference is 
often observed for linezolid combinations against S. aureus (including methicillin-resistant 
strains), some cases of antagonism and synergism were reported and studied in vivo using 
the experimental model of endocarditis. 
 
Fig. 1. Scanning electron micrographs of S. aureus exposed to linezolid (LNZ) at 8 times the 
minimum inhibitory concentration (MIC; magnification, ×50,000) 
Partner drugs Class of antibiotics Interaction Reference(s) 
Vancomycin Glycopeptides Antagonism Grohs et al., 2003; 
Jacqueline et al., 2003; 
Soriano et al., 2005; 
Sahuquillo Arce et al., 2006; 
Singh et al., 2009; 
Gentamicin Aminoglycosides Antagonism 
(inhibition of  the 
early bactericidal 
activity) 
Grohs et al., 2003; 
Jacqueline et al., 2003 
Rifampicin Rifamycins Indifference Grohs et al., 2003; 
Jacqueline et al., 2003; 
Soriano et al., 2005; 
Sahuquillo Arce et al., 2006 
Doxycycline Tetracyclines Addition Sahuquillo Arce et al., 2006 
Ciprofloxacin Grohs et al., 2003 
Levofloxacin 
Quinolones Indifference or 
Antagonism Soriano et al., 2005; 
Sahuquillo Arce et al., 2006 
Acid fusidic -  Grohs et al., 2003 
Fosfomycin - Synergy Sahuquillo Arce et al., 2006 
Imipenem Jacqueline et al., 2005 
Ertapenem 
Carbapenems Synergy 
Jacqueline et al., 2006 
Table 1. In vitro activity of linezolid in combination with partner drugs 
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3.2 In vivo antibacterial activity of linezolid alone and in combination in the 
experimental model of infective endocarditis 
3.2.1 In vivo experimental assessment of linezolid activity: Bacteriostatic agent in 
vivo? 
First reports of linezolid in vivo activity used oral administration (p.o.) of the drug. Given 
that linezolid can be administered intravenously (i.v.) or orally, and no dose adjustment is 
necessary when switching from the i.v. to the oral route of administration in humans (Zyvox 
[package insert], 2000). Infective endocarditis is considered to require maintenance of 
bactericidal levels of antibacterial agents for prolonged periods of time to result in 
eradication of the pathogen. For this reason, it was of special interest to assess the activity of 
the oxazolidinone in this model of endocarditis. Dailey et al investigated the activity of 
linezolid at three different p.o. dosages (25, 50, and 75 mg/kg) against MRSA in rabbits with 
experimental aortic-valve endocarditis (Dailey et al., 2001). After 5 days of treatment, 
linezolid displayed a stepwise decrease in the mean bacterial counts from the valve 
vegetation with a significant decrease for both 50 and 75 mg/kg. Showing a 4- to 5-log 
reduction in valvular bacterial counts, linezolid acted as a bactericidal drug in this study 
(Dailey et al., 2001). 
Based on these results, the authors suggested that linezolid levels at or above the MIC in 
plasma combined with a minimum number of treatment days was required for the 
therapeutic efficacy of linezolid in this model. Further studies were then necessary to 
address the predictive pharmacokinetic and pharmacodynamic (PK/PD) parameters of 
linezolid.  
The extrapolation of results obtained in animal experimental models to human therapy is 
always a difficult task. Owing to the very short spontaneous half-life of linezolid in rabbits 
(30 min; unpublished data) and to the difference in bioavailability of orally administered 
linezolid (approximately 30% bioavailability in rabbits compared to almost 100% in humans 
(Dailey et al., 2001)), the use of simulation of human pharmacokinetics was required to 
reach conclusions relevant to human applications. Simulation is particularly suitable for 
pharmacokinetic and pharmacodynamic analysis, and for the optimization of therapeutic 
efficacy. Computer-controlled simulation (Bugnon et al., 1998) of human kinetic profiles of 
linezolid in rabbits was used in the following study to improve the analysis (Jacqueline et 
al., 2002). The use of a computer-controlled pump allowing an adequate flow of antibiotics 
to be infused into rabbits enabled us to simulate the in vivo human pharmacokinetics of the 
antibiotics. The flow can be adjusted to a profile mathematically defined in time (Bugnon et 
al., 1998). Using this method, the serum linezolid levels obtained after administration of a 
dose simulating a 10-mg/kg dose in humans are shown in Figure 2. The corresponding 
mean peak concentration, area under the curve, and half-life were 11.9±1.1 mg/L, 76.3±5.9 
mg.h/L, and 2.7±0.1 h, respectively, after administration of the first dose and 21.5±1.3 
mg/L, 152.1±9.2 mg.h/L, and 3.4±0.7 h, respectively, at day 5. The increase of linezolid 
concentrations in plasma at day 5 compared to day 1 suggested drug accumulation as 
previously shown by Dailey (Dailey et al., 2001) using the same experimental model.  
Using the computer-controlled simulation, linezolid significantly decreased the bacterial 
counts in aortic valve vegetations from rabbits, but failed to exhibit bactericidal activity, 
despite 5 days of treatment (Figure 3). The comparison with vancomycin administered as a 
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constant-rate intravenous infusion (to obtain a serum steady-state concentration of 
approximately 20 to 25 mg/L) was in favor of the glycopeptide with at least a 5-log10 colony-
forming unit (CFU)/g of vegetation decrease (Figure 3). The oxazolidinone is a time-
dependent antibiotic and for these drugs, the time above the MIC (T>MIC) is usually 
considered a critical parameter in the assessment of therapeutic efficacy (Carbon, 1990). In 
general, the maximal activity of continuous infusion was obtained at a steady-state 
concentration in serum equal to a multiple of the MIC, as previously demonstrated for 
ceftazidime (Cappelletty et al., 1995). To confirm this, continuous infusion of linezolid was 
used by Jacqueline et al (Jacqueline et al., 2002) to investigate whether it improves in vivo 
activity. A switch from intermittent dosing to continuous infusion (using the same total 
daily dose) improved the in vivo activity of linezolid against two strains of MRSA. By 
increasing the time above the MIC (T>MIC of 100%), linezolid continuous infusion achieved 
bactericidal activity in vivo with a >3-log10-decrease as compared to the control animals 
(Figure 4).  
 
Fig. 2. Linezolid concentrations in plasma after simulation of a dose corresponding to a 10 
mg/kg dose in humans (i.e., 600 mg). Circles, concentrations obtained after administration 
of the first dose; Triangles, concentrations obtained at day 5. Error bars represent standard 
deviations (adapted from Jacqueline et al., 2002) 
Further studies are needed to investigate the potential clinical benefit of continuous 
infusion, which could be an appropriate alternative to the use of glycopeptides for the 
treatment of severe MRSA infections. Although no superiority of continuous infusion vs. 
intermittent dosing was demonstrated in a clinical study with critically ill septic patients 
(Adembri et al., 2008), Adembri et al showed that the continuous infusion modality has a 
theoretical advantage over intermittent infusion in the treatment of infection in these 
patients. Finally, there is a clear need for more powerful clinical trials to demonstrate the 
potent clinical benefit and the safety of this administration modality. 
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Fig. 3. In vivo activity of linezolid (human-equivalent of 600 mg q12hr, intermittent dosing, 
ID) and vancomycin (continuous infusion, CIV) against MRSA 1 (black) and MRSA 2 (grey) 
strains after a 5-day treatment. Error bars represent standard deviations (adapted from 
Jacqueline et al., 2002) 
 
Fig. 4. Impact of the administration mode (intermittent dosing, ID vs. continuous infusion, 
CIV) on the in vivo activity of linezolid. Control animals (black); Linezolid ID (grey); 
Linezolid CIV (white). Error bars represent standard deviations (adapted from Jacqueline et 
al., 2002) 
3.2.2 Improvement of the in vivo activity of linezolid by adding a partner drug: What is 
the good choice? 
Infective endocarditis is considered to require bactericidal drugs to achieve clinical efficacy 
and/or microbiological eradication. Like most protein synthesis inhibitors, oxazolidinones 
www.intechopen.com
 
Endocarditis 
 
104 
are bacteriostatic agents. Clinicians need to combine linezolid with another drug to (i) 
increase the bactericidal activity of therapy, (ii) prevent the emergence of drug-resistant 
subpopulations, and (iii) provide a complementary antibacterial spectrum. Moreover, the 
use of synergistic antibiotic combinations is appealing as a way to optimize therapy for 
infective endocarditis, especially when the causative pathogen is resistant (such as MRSA). 
Although in vitro interactions between linezolid and agents are well-documented (Table 1), 
the presence of in vitro synergism or antagonism and in vivo correlation or enhanced 
clinical outcome is not easy to highlight. In addition, the in vitro-in vivo correlation of either 
positive or negative interactions between two drugs can be difficult to assess and 
discrepancies occur.  
3.2.2.1 Linezolid plus vancomycin 
Although the combination of linezolid with vancomycin is not the most obvious choice, 
many papers have investigated the in vitro activity of this combination and have concluded 
they are antagonistic. Using the endocarditis model, Chiang et al have tested this association 
against an MRSA strain and they demonstrated that vancomycin alone was more effective 
than either linezolid alone or the combination of linezolid and vancomycin (Figure 5) 
(Chiang & Climo, 2003). This study is in line with in vitro reports (Grohs et al., 2003; 
Jacqueline et al., 2003) and the combination of linezolid plus vancomycin should be avoided 
in clinical practice. 
 
Fig. 5. Outcome of 5-day treatment of experimental MRSA endocarditis. (adapted from 
Chiang & Climo, 2003) 
3.2.2.2 Linezolid plus gentamicin 
Linezolid, when added to gentamicin, seemed to inhibit the early in vitro bactericidal 
activity of gentamicin, particularly over the first 6 h (Jacqueline et al., 2003). During this 
interval, inhibition of the bactericidal activity of gentamicin was dependent on the linezolid 
concentration. Aminoglycosides are bactericidal, concentration-dependent antibiotics that 
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act by creating fissures in the outer membrane of the bacterial cell (Gonzalez & Spencer, 
1998). A combination of these agents with linezolid could be useful to increase the 
bactericidal activity of the therapy, especially during the first days of treatment.  
Given that the presence of in vitro antagonism is not always correlated with in vivo failure, 
Jacqueline et al assessed the combination of linezolid plus gentamicin in the endocarditis 
model against two clinical strains of MRSA exhibiting MICs of 0.125 and 0.5 mg/L 
(Jacqueline et al., 2004). Using a human-like pharmacokinetic simulation for linezolid and 
gentamicin, the combination demonstrated a bactericidal activity against the two strains 
with a decrease of at least 4 log10 CFU/g of vegetation compared with controls. PK/PD 
aspects could probably explain the difference observed between the in vitro and in vivo 
activities. Contrary to constant concentrations in time-kill curves experiments, the 
concentrations of linezolid and gentamicin added to the vegetation changed over time. 
Although previous in vitro results suggest an antagonism, linezolid combined with 
gentamicin could be of clinical interest for the treatment of severe MRSA infections 
requiring combination antimicrobial therapy. 
3.2.2.3 Linezolid plus rifampicin 
Rifampicin is an RNA polymerase inhibitor that blocks bacterial transcription. Rifampicin is 
used clinically only as a part of combination regimens because development of resistance is 
rapid (Heep et al., 2000). In addition to its use against Mycobacterium tuberculosis, rifampicin 
is very useful in the management of bone and joint infections due to MRSA. Indifference 
was the main interaction observed in vitro between linezolid and rifampicin (Grohs et al., 
2003; Jacqueline et al., 2003, Soriano et al., 2005; Sahuquillo Arce et al., 2006). The addition of 
linezolid prevented the selection of rifampicin resistant mutants after 24 h of incubation at 
37°C. Consequently, a synergistic interaction can be considered by inhibition of the 
emergence of the resistance development. 
By evaluating the bactericidal activity, synergy, and emergence of antimicrobial resistance, 
Dailey et al assessed the potent activity of linezolid plus rifampicin in the endocarditis 
model against a MSSA strain (rifampicin MIC<= 0.12 mg/L) (Dailey et al., 2003). After a  
5-day treatment, the combination showed no in vivo antagonism between the drugs. As 
with in vitro tests, indifference was observed and the combination inhibited the emergence 
of rifampicin resistance. These data support a clinical interest in the treatment of infections 
due to S. aureus. A similar study was performed against an MRSA strain (rifampicin MIC= 2 
mg/L) and indifference between linezolid and rifampicin was observed (Tsaganos et al., 
2008). Moreover, this work demonstrated that (i) linezolid limited bacterial growth in the 
secondary foci of endocarditis, and (ii) that the combination favored the suppression of 
bacterial growth in the lung. 
3.2.2.4 Linezolid plus carbapenems 
Beta-lactam antibiotics act by inhibiting penicillin-binding proteins (PBPs) that are involved 
in peptidoglycan synthesis. Penicillin-binding protein 2A (PBP2A) is the protein responsible 
for the methicillin resistance mechanism in S. aureus. Methicillin resistance confers resistance 
to all the beta-lactams, including cephalosporins and carbapenems; however, many studies 
have reported a potent efficacy of imipenem against S. aureus when used in combination 
with other antimicrobial agents, including fosfomycin (Nakazawa et al., 2003), vancomycin 
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(Totsuka K et al., 1999; Benquan et al., 2002; Rochon-Edouard et al., 2000), and 
cephalosporins (Uete & Matsuo et al., 1995).  
In vitro synergy between linezolid and carbapenems can be difficult to achieve; sub-
inhibitory concentrations of the carbapenem must be used with linezolid to achieve synergy 
and higher concentrations can lead to an antagonism (Jacqueline, 2005, 2006). The infective 
endocarditis model was very useful to assess in vivo interaction. Continuous infusion of 
imipenem alone, the first carbapenem tested in this model, showed no activity against 
MRSA after 5 days of treatment (Jacqueline et al., 2005). The aim of using continuous 
imipenem infusion was to obtain an in vivo steady-state concentration that mimics the in 
vitro conditions so that synergy was observed as soon as possible (i.e., to achieve a target 
concentration of 1/32 the MIC for each strain). Using these conditions, linezolid plus 
imipenem exhibited bactericidal and synergistic activities against two MRSA strains, with at 
least a 4-log10 CFU/g decrease compared to the counts for the controls. Subsequent to that 
study, the carbapenem ertapenem was investigated in combination with linezolid using the 
same experimental model (Jacqueline et al., 2006). Ertapenem is a parenteral carbapenem 
antibiotic with a broad antibacterial spectrum and once-a-day dosing that is supported by 
clinical studies and an extended half-life (Zhanel et al., 2005). In this study, animals were 
randomly assigned to receive either no treatment (controls), a linezolid regimen mimicking 
the human dose of 10 mg/kg/12 h, an ertapenem regimen mimicking the human dose of 1 
g/day, or a combination of both regimens. As previously observed with imipenem and 
confirming the in vitro data, linezolid and ertapenem exhibited a highly bactericidal and 
synergistic activity in vivo against three MRSA strains after 4 days of treatment (Figure 6). 
Due to the once-daily dosing of ertapenem and availability of an oral form for linezolid, this 
combination opens new therapeutic avenues in the field of severe Gram-positive bacterial 
infections, including an option for outpatient parenteral antimicrobial therapy. 
 
Fig. 6. In vivo synergy between linezolid (LZO) and ertapenem (ETP) against an MRSA 
strain in the endocarditis model. Error bars represent standard deviations (adapted from 
Jacqueline et al., 2006) 
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4. Quinupristin-dalfopristin: A therapeutic option for MRSA endocarditis? 
Streptogramins inhibit protein synthesis by binding to the ribosomal 50S subunit, and the 
most frequent mechanism of quinupristin resistance encountered is target modification by 
methylation of an adenine residue in 23S rRNA (encoded by the ermA, ermB, or ermC gene). 
Constitutively expressed erm genes confer in vitro cross-resistance to macrolides, 
lincosamides, and streptogramin B. Quinupristin and dalfopristin are water-soluble 
injectable streptogramin B and streptogramin A antibiotics, respectively, whose combination 
in a 30:70 (wt/wt) ratio acts synergistically on Gram-positive bacteria (Bouanchaud, 1992). 
Despite in vitro susceptibility to quinupristin-dalfopristin, mutations in the L22 ribosomal 
protein are correlated with resistance to quinupristin in S. aureus (Bruni et al., 2000). The 
experimental model of infective endocarditis was used to address the efficacy of 
quinupristin-dalfopristin against susceptible and resistant S. aureus strains to quinupristin 
(but not quinupristin-dalfopristin). If quinupristin-dalfopristin remained active against 
quinupristin-susceptible MRSA after 4 days of treatment, a significant decrease of the 
activity was observed against a quinupristin-resistant strain. Nevertheless, the impact of the 
resistance on the activity of the combination can differ between studies (Batard et al., 2002; 
Pavie et al., 2002).  
Combination with vancomycin improved the in vivo activity for susceptible and resistant 
strains (Pavie et al., 2002), but the benefit was less important against the resistant MRSA. 
Despite clinical interest in adding gentamicin (aminoglycosides) to quinupristin-
dalfopristin, the combination showed no additive benefit against two MRSA strains (Batard 
et al., 2002). Although the lack of benefit may be due to the high efficacy of the 
monotherapies, these data did not argue for its use in clinical practice. 
5. Daptomycin: Experimental evaluation of an old new drug 
Daptomycin, previously called LY 146032, was first discovered in the 1980s by researchers at 
Eli Lilly, but an increase in creatine phosphokinase  levels in serum in early clinical trials 
(probably related to skeletal muscle toxicity) led to initial abandonment of this promising 
compound (Tally & DeBruin, 2000).  
Daptomycin is a novel lipopeptide antibiotic active against Gram-positive bacteria, 
including MRSA strains. It disrupts the bacterial cell membrane by forming transmembrane 
channels, and causes a calcium-dependent depolarization of the cellular membrane and 
inhibition of macromolecular synthesis leading to cell death (Silverman et al., 2003).  
Daptomycin is a potential alternative to vancomycin for the treatment of severe MRSA 
infections, with benefits such as once-daily dosing, the lack of need for monitoring serum 
concentrations, and FDA approval for the treatment of right-sided endocarditis (Cubist, 
2003). In vitro, the lipopeptide exerts its bactericidal action in a rapid (60 min) and 
concentration dependent way exhibiting more powerful activity than glycopeptides. 
5.1 In vivo antibacterial activity of daptomycin: More bactericidal than glycopeptides?  
The endocarditis model was used to assess the activity of daptomycin against MRSA and to 
confirm the highly bactericidal activity observed in vitro, especially in comparison with the  
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reference drug, vancomycin. Effectiveness against three MRSA strains, including one GISA 
strain (MU50), was tested using computer-controlled simulation to mimic the human dose 
of 6 mg/kg once daily (Jacqueline et al., 2011). After 4 days of treatment, daptomycin 
performed well against MSSA, MRSA, and GISA strains (daptomycin MIC= 0.5 mg/L) with 
a decrease of 5 log10 CFU/g (Figure 7).  
More than 20 years ago, Kennedy & Chambers evaluated the potent in vivo activity of 
daptomycin, known at that time as a vancomycin-like lipopeptide, against S. aureus 
(Kennedy & Chambers, 1989). Vancomycin (25 mg/kg twice daily) was as effective as 
daptomycin (once-daily dose of 10 mg/kg) against both MSSA and MRSA strains in the 
endocarditis model. The next year Kaatz et al compared daptomycin (8 mg/kg q8hr) with 
the glycopeptides, vancomycin and teicoplanin (Kaatz et al., 1990). The conclusion of the 
study was interesting:  
“We have established that, in the rabbit model and against the S. aureus test strains we used, 
daptomycin and teicoplanin-HD are as efficacious as vancomycin, but for certain strains of 
S. aureus, diminished susceptibility to both can develop during therapy” (Kaatz et al., 1990). 
Also at that time, the authors highlighted an important characteristic of daptomycin, its 
rapid propensity to select resistant variants during therapy. Despite high in vivo bactericidal 
activity, experimental models were not able to demonstrate that the rapid bactericidal 
activity of daptomycin observed in vitro was correlated with a better outcome in vivo than 
glycopeptides, vancomycin, or teicoplanin. 
 
Fig. 7. In vivo activity of daptomycin (human-equivalent (HE) at 6 mg/kg/24 h) against 
MSSA, MRSA, and GISA strains after a 4-day treatment. Control animals (black); 
daptomycin-treated animals (grey). Error bars represent standard deviations (adapted from 
Jacqueline et al., 2011) 
5.2 Emergence of daptomycin-resistance during therapy 
The experimental endocarditis model is not considered an appropriate model for detection 
of the emergence of resistant variants. Nevertheless, emergence of daptomycin-resistant 
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variants was observed after only 4 days of therapy in a model using human-equivalent 
dosage (Jacqueline et al., 2011), as previously shown by Kaatz et al (Kaatz et al., 1990).  This 
strongly suggests that combination therapy may be useful for daptomycin treatment of S. 
aureus infections. In the study by Jacqueline et al, the 6 mg/kg dosage regimen did not 
prevent the emergence of resistance in two animals (one in the MSSA group (8 animals) and 
one in the MRSA group (7 animals)) (Figure 8). Moreover, detection of resistant variants was 
correlated with a failure of daptomycin treatment in those animals. These data support the 
use of daptomycin dosages exceeding 6 mg/kg to increase bacterial killing and limit the risk 
of emergence of resistant variants during daptomycin therapy. Case reports have described 
safe and well tolerated daptomycin treatment at doses up to 12 mg/kg (Benvenuto et al., 
2006; Cunha et al., 2006), but adequate dosing of daptomycin remains unresolved. A recent 
review about clinical utility of daptomycin in infective endocarditis specifies that adequate 
dosing of daptomycin for the treatment of left-sided or prosthetic valve S. aureus 
endocarditis should be ≥ 10 mg/kg/day (Cervera et al., 2011). 
 
Fig. 8. Bacterial titers in vegetations infected by methicillin-susceptible S. aureus after 4 days 
of treatment with daptomycin (human-equivalent of 6 mg/kg once-daily). Arrows indicate 
animals with isolates exhibiting increased MICs to daptomycin (adapted from Jacqueline et 
al., 2011) 
5.3 What partner drugs to use with daptomycin? An unresolved question 
Faced with rapid emergence of daptomycin-resistant variants during therapy, clinicians 
should use a combination to limit the risk of resistance development. Rifampicin and 
gentamicin are often used in combination with antibacterial agents such as glycopeptides, 
beta-lactams, or linezolid. Two studies investigated the in vivo activity of daptomycin alone 
and in combination with rifampicin or gentamicin against different MRSA strains (LaPlante 
& Woodmansee, 2009; Miró et al., 2009). In experiments simulating human PK for all 
studied drugs, Miro et al demonstrated that daptomycin plus gentamicin was as effective as 
daptomycin alone (P=0.83). In addition, both were more active than daptomycin plus 
rifampicin (P<0.05) (Miró et al., 2009). Using an in vitro pharmacodynamic infection model 
with simulated endocardial vegetations, LaPlante & Woodmansee showed that daptomycin 
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monotherapy displayed better activity than daptomycin in combination with rifampicin or 
gentamicin (LaPlante & Woodmansee, 2009). These experimental data strongly show that 
the addition of gentamicin or rifampicin does not aid the in vivo activity of daptomycin. In 
vitro, Miro et al (Miro et al., 2009) showed a synergistic interaction between daptomycin and 
fosfomycin against MSSA and MRSA. Further in vivo and clinical studies are strongly 
needed to determine effective combinations for avoiding the emergence of resistance to 
daptomycin. 
6. Tigecycline 
Tigecycline is the first clinically-available member of a new class of broad-spectrum 
antibacterials, the glycylcyclines, which were specifically developed to overcome the two 
major mechanisms of tetracycline resistance (Zhanel et al., 2004). By binding to the 30S 
ribosomal subunit, tigecycline blocks the entry of aminoacyl-tRNA into the A site of the 
ribosome during translation (Slover et al., 2007). Like other protein synthesis inhibitors, the 
drug is bacteriostatic. Tigecycline is an obvious choice to treat MRSA endocarditis, however 
its potent in vitro activity against MRSA suggests that it should be used as a last resort. 
Few studies have valuated the activity of tigecycline in experimental model of MRSA 
endocarditis. A study using a rat model of endocarditis showed a dose-effect relationship, 
with a >2-log10 decrease in bacterial counts with doses greater than 10 mg/kg/day for the 
course of treatment (Murphy et al., 2000). Using a computer-controlled simulation 
mimicking the human dose of 100 mg initially, followed by 50 mg twice daily, tigecycline 
demonstrated a significant and homogeneous activity against MSSA, MRSA, and GISA 
strains (Jacqueline et al., 2011). Nevertheless, the drug failed to exhibit a bactericidal effect 
versus the effect of the control treatment, despite 4 days of treatment (reduction, 2-log10 
CFU/g compared with the controls) (Figure 9). This moderate activity could be improved  
 
Fig. 9. In vivo outcome after a 4-day treatment of tigecycline (human-equivalent of 100 mg 
initially, followed by 50 mg twice daily) against MSSA, MRSA, and GISA strains. Control 
animals (black); tigecycline-treated animals (grey). Error bars represent standard deviations 
(adapted from Jacqueline et al., 2011) 
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by the use of a partner drug in combination with tigecycline. The addition of gentamicin 
significantly improved the killing activity of tigecycline in biofilm-forming S. aureus using 
an in vitro pharmacodynamic model (McConeghy KW & LaPlante, 2010). Finally, studies 
conducted in both animals and humans have demonstrated that tigecycline distributes 
widely into various tissues and body fluids (Rello, 2005), and peak serum concentrations do 
not exceed 1 mg/L, which may limit its utility in the treatment of bacteraemia and 
endocarditis (Paterson, 2006). The recommended dosage of tigecycline may be too low for 
the treatment of severe infections and assessment of higher doses in severe experimental 
animal models is needed. 
7. Anti-MRSA cephalosporins exhibiting high affinity for PBP2A:  
A revolution? 
PBPs catalyze transpeptidase or transglycosidase reactions, and are essential for the final 
stages of peptidoglycan synthesis (Spratt, 1977). β-lactam antibiotics, including penicillins 
and cephalosporins, inhibit PBPs. β-lactams are widely used because of their broad-
spectrum activity and favorable safety profiles (Darville & Yamauchi, 1994). MRSA strains 
are  not susceptible to the action of β-lactams because of the low affinity of β-lactams for 
PBP2a, an additional PBP encoded by the mecA gene and conferring methicillin resistance 
(Lim & Strynadka, 2002). Because β-lactam antibiotics are usually considered the most 
effective therapeutic option against S. aureus infections, researchers have sought to increase 
the affinity of β-lactams for the modified PBP2a.  This is illustrated by the development of 
two cephalosporins, namely ceftobiprole and ceftaroline, which have potent antimicrobial 
activities against both Gram-positive (including MRSA) and Gram-negative bacteria. 
Ceftaroline binds to the four natural PBPs in S. aureus, but has maximum affinity for PBP2a 
(Villegas-Estrada et al., 2008). Because the marketing authorization for ceftobiprole was 
withdrawn in the United States and the European Union due to unfavorable assessments of 
the applications, ceftaroline is better studied.   
7.1 Ceftaroline, a broad-spectrum cephalosporin active against MRSA 
Ceftaroline is a novel broad-spectrum cephalosporin with potent activity against MRSA 
strains due to its strong affinity for S. aureus PBPs, including PBP2a, encoded by the 
methicillin resistance gene mecA (Lim & Strynadka, 2002). Ceftaroline acetate (PPI-0903) is 
an N-phosphono-water-soluble prodrug rapidly metabolized in vivo into the bioactive 
metabolite ceftaroline (PPI-0903 M). In vitro, bactericidal activity (≥3 log10 CFU/mL 
reductions) and time-dependent killing was observed for the cephalosporin from 4 times the 
MIC against an MRSA strain (Figure 10). Ceftaroline in vivo activity was assessed against 
two MRSA strains isolated from blood cultures (Jacqueline et al, 2007). The MRSA strain 
exhibited heterogeneous high-level methicillin resistance (methicillin MIC =128 mg/L), and 
the heterogeneous glycopeptide- intermediate S. aureus strain (hGISA) exhibited homogeneous 
resistance to methicillin (methicillin MIC >1,024 mg/L) and heterogeneous resistance to 
glycopeptides. Ceftaroline MICs/MBCs were 1/1 and 2/2 mg/L for the MRSA and hGISA 
strain, respectively. A human-like simulation was intended to provide apparent values of 
pharmacokinetic parameters close to those observed in healthy volunteers after a 1-h 
infusion of a 600-mg dose (approximately 10 mg/kg) of ceftaroline acetate: mean half-life   
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Fig. 10. In vitro activity of ceftaroline against methicillin-resistant S. aureus. Control (circles); 
ceftaroline at 1×MIC (diamonds); ceftaroline at 4×MIC (triangles), ceftaroline at 8×MIC 
(squares) (Author’s unpublished data) 
(t1/2), 1.57 to 2.63 h; peak concentration (Cmax), 18.96 to 21.02 mg/L; and area under the 
curve (AUC), 56.08 mg.h/L (Cerexa, Inc., unpublished data). After simulation into the rabbit, 
the corresponding Cmax, AUC, and t1/2 values were 21.9±3.0 mg/L, 71.2 mg.h/L, and 2.4 h, 
respectively (Figure 11). Ceftaroline in vivo activity was assessed against two MRSA strains 
isolated from blood cultures (Jacqueline et al, 2007). The MRSA strain was a strain with 
heterogeneous high-level methicillin resistance (methicillin MIC =128 mg/liter), and 
 
Fig. 11. Pharmacokinetics of ceftaroline in plasma after administration of a dose simulating a 
600-mg dose in humans (dashed lines) and the corresponding human pharmacokinetics in 
animals (solid line) (adapted from Jacqueline et al., 2007) 
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the heterogeneous glycopeptide- intermediate S. aureus strain (hGISA) exhibited homogeneous 
resistance to methicillin (methicillin MIC >1,024 mg/liter) and heterogeneous resistance to 
glycopeptides. 
Ceftaroline MICs/MBCs were 1/1 and 2/2 mg/L for the MRSA and hGISA strain, 
respectively. A human-like simulation was intended to provide apparent values of 
pharmacokinetic parameters close to those observed in healthy volunteers after a 1-h 
infusion of a 600-mg dose (ca. 10 mg/kg) of ceftaroline acetate: mean half-life (t1/2), 1.57 to 
2.63 h; peak concentration (Cmax), 18.96 to 21.02 mg/liter; and area under the curve (AUC), 
56.08 mg.h/liter (Cerexa, Inc., unpublished data). After simulation into the rabbit, the 
corresponding Cmax, AUC, and t1/2 values were 21.9±3.0 mg/liter, 71.2 mg.h/liter, and 2.4 
h, respectively (Figure 11). 
In this study, Jacqueline et al evaluated the in vivo activity of ceftaroline in comparison with 
vancomycin and linezolid, the two main therapeutic options available for the treatment of 
severe MRSA infections. In vivo outcome after a 4-day treatment is shown in Figure 12. 
Ceftaroline demonstrated excellent bactericidal and homogeneous activity against MRSA in 
the endocarditis model with at least a 6-log10 CFU/g decrease as compared to the control 
animals. In comparison, linezolid displayed moderate activity with a 2-log10 decrease. 
Vancomycin was as effective as ceftaroline against the MRSA strain (vancomycin MIC = 1 
mg/L), but showed only bacteriostatic activity against the hGISA strain (vancomycin MIC = 
4 mg/L). In addition, ceftaroline was able to sterilize 90% and 60% of the vegetations 
produced by the MRSA or hGISA strain, respectively, whereas vancomycin achieved 
sterilization of 67% and 0% of the vegetations, respectively.  
 
Fig. 12. Bacterial titers in vegetations infected by MRSA or hGISA strains after 4 days of 
treatment with ceftaroline (human-equivalent of 600 mg twice daily), linezolid (human-
equivalent of 600 mg twice daily), and vancomycin (continuous infusion targeting a serum-
steady state concentration of 25 mg/L). Control animals (black); ceftaroline-treated animals 
(grey), linezolid-treated animals (dashed lines), vancomycin-treated animals (white). Error 
bars represent standard deviations (adapted from Jacqueline et al., 2007) 
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Fig. 13. Bacterial titers in vegetations infected by MRSA after 4 days of treatment with 
ceftobiprole medocaril (formerly BAL9141) (19 mg/kg of active drug [ceftobiprole] 
administered intramuscularly thrice daily), daptomycin (intravenous 18 mg/kg once daily), 
vancomycin (intravenous 30 mg/kg twice daily), and linezolid (75 mg/kg administered 
subcutaneously three times daily). Control animals (black); ceftaroline-treated animals 
(grey), linezolid-treated animals (dashed lines), vancomycin-treated animals (white). Error 
bars represent standard deviations (adapted from Tattevin et al., 2010) 
 
Fig. 14. Bacterial titers in spleens and kidneys after 4 days of treatment with ceftobiprole 
medocaril (formerly BAL9141) (19 mg/kg of active drug [ceftobiprole] administered 
intramuscularly thrice daily), daptomycin (intravenous 18 mg/kg once daily), vancomycin 
(intravenous 30 mg/kg twice daily), and linezolid (75 mg/kg administered subcutaneously 
three times daily). Spleen bacterial counts (black); Kidney bacterial counts (white). Error 
bars represent standard deviations (adapted from Tattevin et al., 2010) 
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Endocarditis studies evaluating the activity of ceftaroline are very limited. However, 
Tattevin et al have assessed the activity of ceftobiprole (formerly BAL9141), the other anti-
MRSA cephalosporin with high affinity for PBP2a, against MRSA in comparison with 
vancomycin, linezolid, and daptomycin (Tattevin et al, 2010). Using experimental conditions 
similar to the conditions used by Jacqueline et al, they showed that the burdens of 
organisms in vegetations were significantly lower in ceftobiprole-treated rabbits than in 
rabbits treated with vancomycin, linezolid, or daptomycin (4-day treatment) (Figure 13). 
Moreover, the bacterial titers in spleens and in kidneys were significantly lower in 
ceftobiprole treated animals than in animals treated by linezolid or vancomycin (Figure 14). 
A study comparing ceftaroline and daptomycin, and using human-projected doses, 
demonstrated that both antimicrobial agents displayed highly bactericidal activity against S. 
aureus strains but ceftaroline achieved 100% sterilization of the vegetations infected by the 
MSSA, MRSA or GISA strains, whereas daptomycin sterilized 62%, 57% and 100% of the 
vegetations, respectively (Jacqueline et al., 2011). 
7.2 Assessment of intramuscular administration of ceftaroline 
Pathogens such as MRSA are becoming more virulent and are no longer confined to acute-
care settings. There is a clinical need for new antibiotics that can be administered by 
intramuscular (IM) injection, facilitating outpatient antibiotic therapy for MRSA. The goals 
of the following experiments were to compare the pharmacokinetic parameters of 
ceftaroline after intravenous and IM administration and evaluate the in vivo activity of 3 
different doses of ceftaroline against MRSA compared with teicoplanin as a positive control 
after IM administration by using an aortic valve endocarditis rabbit model (Jacqueline et al., 
2010).  
Six animals were divided into 2 groups, and a 20-mg/kg dose of the prodrug ceftaroline 
acetate was administered by IM injection into the right thigh or by a short intravenous 
infusion. Blood samples were obtained from the animals over 8 h (5, 10, 15, 30, and 45 min, 
and 1, 2, 4, and 8 h post-dose). Results suggest that ceftaroline has an excellent 
pharmacokinetic profile after IM administration. Bioavailability of IM administration 
exceeded 90% of intravenous infusion as calculated by AUC (Table 2). Cmax was decreased 
with IM administration compared with intravenous infusion as ceftaroline was slowly 
released from the IM injection site. After IM administration of 5-, 20-, and 40-mg/kg doses, 
the Cmax increased approximately in proportion to dose (5.18, 15.75, and 37.85 mg/L, 
respectively) and plasma half-life increased from 0.74 to 1.14 h (Figure 15). Compared with a 
short intravenous infusion, IM administration of ceftaroline resulted in longer plasma half-
life and percentage of time that the concentration of ceftaroline remained above the MIC 
(%T>MIC), which is the most critical pharmacokinetic-pharmacodynamic parameter for 
efficacy (Table 2) (Andes & Craig, 2006).  
Using the well-established rabbit endocarditis model, experimental endocarditis was 
induced with an inoculum of 108 CFU of a MRSA strain (ceftaroline MIC = 1 mg/L) with 
heterogeneous high-level methicillin resistance (methicillin MIC = 128 mg/L). Treatment 
was started 24 h after inoculation and antibiotics (ceftaroline and teicoplanin) were 
administered twice daily using the IM route for 4 days. Animals were randomly assigned to 
no treatment (controls), ceftaroline 40 mg/kg IM twice daily, ceftaroline 20 mg/kg IM twice 
daily, ceftaroline 5 mg/kg IM twice daily, or teicoplanin 20 mg/kg IM twice daily.  
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Ceftaroline 20 mg/kg Pharmacokinetic 
parameter IM administration  IV administration  
Cmax (mg/L) 16.1 ± 0.7 84.0 ± 7. 5 
Tmax (minutes) 30 5 
t1/2 (hours) 0.9 ± 0.3 0.2 ± 0.00 
AUC0-8h (mg●h/L) 26.5 ± 2.9 29.2 ± 3. 9 
%T>MICa (8-h period) 46.3 ± 2.0 22.5 ± 1.9 
%T>MICa (12-h period) 30.9 ± 1.3 15.0 ± 1.3 
aMethicillin-resistant Staphylococcus aureus (MRSA) strain with ceftaroline MIC = 1 mg/L. 
AUC = area under the concentration-time curve; Cmax = peak concentration; Tmax = time to peak 
concentration; t1/2 = half-life; %T>MIC = time that drug levels in the serum remained above the 
MIC (Author’s unpublished data). 
Table 2. Pharmacokinetic parameters following single-dose intramuscular (IM) 
administration or short intravenous (IV) infusion of ceftaroline (mean ± SD) 
 
Fig. 15. Ceftaroline concentrations after intramuscular (IM) and intravenous (IV) 
administration in the rabbit (mean ± SD). ■ = 5-mg/kg IM dose; ▲= 20-mg/kg IM dose;  
● = 40-mg/kg IM dose; × = 20-mg/kg intravenous dose (Author’s unpublished data) 
The in vivo outcome after a 4-day treatment regimen and the rate of sterilization of the 
vegetations produced by the MRSA strain are shown in Table 3 (Jacqueline et al., 2010).  
A dose-dependent response was observed with sterilization rates for ceftaroline of 100%, 
80%, and 33% for the 40-mg/kg, 20-mg/kg, and 5-mg/kg doses of ceftaroline, respectively. 
The difference between 20-mg/kg and 40-mg/kg doses was not statistically significant 
(P>0.05). In vivo bactericidal activity was consistent across all animals tested at the 40-
mg/kg dose and for 9 of 10 animals at the 20-mg/kg dose of ceftaroline.    
The %T>MICs attained with IM administration in this model were associated with 
bactericidal activity against MRSA (Tables 2 and 3). The efficacy of IM ceftaroline was 
similar to that achieved previously with intravenous ceftaroline administered in a regimen 
simulating the human dose (i.e., 600 mg twice daily) (Jacqueline et al., 2007). As expected, 
the positive control teicoplanin at 20 mg/kg IM displayed activity against the MRSA strain, 
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with a sterilization rate of 60%, and bacterial titers similar to those observed with 
vancomycin against the same MRSA strain (Jacqueline et al., 2007). Currently, teicoplanin is 
the only anti-MRSA drug approved as an IM injection; however, it is not available in the 
United States. Ceftaroline may be a valuable option for the IM treatment of MRSA 
infections. These findings are consistent with a favorable IM pharmacokinetic profile and 
strongly support the development of IM ceftaroline as a promising and effective therapeutic 
option for the treatment of severe MRSA infections. 
 
Regimen 
Mean ± SD log10 CFU/g of vegetation 
(no. of sterile veg./total no. of veg.) (%) 
Controls 8.99 ± 0.47 (0/10) (0) 
IM ceftaroline 40 mg/kg 2.45 ± 0.14 (10/10) (100)a,b,c 
IM ceftaroline 20 mg/kg 3.14 ± 1.38 (8/10) (80)a,d 
IM ceftaroline 5 mg/kg 5.26 ± 2.73 (3/9) (33)a 
IM teicoplanin 20 mg/kg 3.07 ± 0.66 (6/10) (60)a,d 
a P<0.001 vs controls; b P<0.001 vs IM ceftaroline 5-mg/kg regimen; Bonferroni’s test after analysis of 
variance. c The titers for vegetations from all animals in the group were below the limit of detection.  
d P<0.05 vs IM ceftaroline 5-mg/kg regimen. IM = intramuscular. 
Table 3. Bacterial titers in vegetations after 4 days of treatment with IM ceftaroline (5, 20, 
and 40 mg/kg) and IM teicoplanin (20 mg/kg) (adapted from Jacqueline et al., 2010) 
8. Conclusions 
Antimicrobial therapy is the cornerstone of the treatment of infective endocarditis. Although 
vancomycin still remains the standard treatment for severe MRSA infections, new 
therapeutic options are now available for the treatment of MRSA infective endocarditis. 
Introduction of linezolid, the first member of the oxazolidinone class, in the early 2000s, 
opened a new field of investigation that demonstrated that vancomycin was not the only 
solution against MRSA infections. Although linezolid was not the most effective option for 
endocarditis treatment, studies with the oxazolidinone demonstrated that experimental 
animal models are essential to (i) develop better understanding of the in vivo activity of a 
new drug, (ii) obtain important information not present in clinical trials.  
Among the new recently available antimicrobial agents, experimental data strongly support 
daptomycin as an effective option in the treatment of MRSA endocarditis. The lipopeptide 
demonstrated homogeneous in vivo bactericidal activity against S. aureus, including 
methicillin-susceptible, methicillin-resistant, and glycopeptide-intermediate strains. Taking 
advantage of favourable drug pharmacokinetics (once-daily administration), daptomycin 
should be considered as a valuable alternative to vancomycin. Nevertheless, clinical use of 
daptomycin merit further investigation due to unresolved questions, such as adequate 
dosing, emergence of resistance during treatment, and appropriate combination therapy.  
Ceftaroline fosamil (prodrug of the active metabolite) is a new, broad-spectrum 
cephalosporin recently approved in the USA for the treatment of acute bacterial skin and 
skin structure infections and community-acquired bacterial pneumonia. Data from both 
clinical trials (Corey et al., 2010; Wilcox et al., 2010; Rank et al., 2011) and animal studies 
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confirmed ceftaroline as a very promising new cephalosporin for the treatment of serious 
MRSA infections.  Given its safety profile, bactericidal activity, and excellent activity against 
S. aureus, ceftaroline should play an important role in the treatment of MRSA infective 
endocarditis in the coming years. 
9. References 
Adembri, C., Fallani, S., Cassetta, M.I., Arrigucci, S., Ottaviano, A., Pecile, P., Mazzei, T., De 
Gaudio, R. & Novelli, A. (2008). Linezolid pharmacokinetic/pharmacodynamic 
profile in critically ill septic patients: intermittent versus continuous infusion. 
International Journal of Antimicrobial Agents, Vol.31, No.2, pp. 122-129. 
Andes, D. & Craig, W.A. (2006). Pharmacodynamics of a new cephalosporin, PPI-0903 
(TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh 
and lung infection models: identification of an in vivo pharmacokinetic-
pharmacodynamic target. Antimicrobial Agents and Chemotherapy, Vol.50, No.4, pp. 
1376–1383. 
Aoki, H., Ke, L., Poppe, S.M., Poel, T.J., Weaver, E.A., Gadwood, R.C., Thomas, R.C., 
Shinabarger, D.L. & Ganoza, M.C. (2002). Oxazolidinone antibiotics target the P site 
on Escherichia coli ribosomes. Antimicrobial Agents and Chemotherapy, Vol.46, No.4, 
pp. 1080–1085. 
Batard, E., Jacqueline, C., Boutoille, D., Hamel, A., Drugeon, H.B., Asseray, N., Leclercq, R., 
Caillon, J., Potel, G. & Bugnon, D. (2002). Combination of quinupristin-dalfopristin 
and gentamicin against methicillin-resistant Staphylococcus aureus: Experimental 
rabbit endocarditis study. Antimicrobial Agents and Chemotherapy, Vol.46, No.7, pp. 
2174-2178. 
Benquan, W., Yingchun, T., Kouxing, Z., Tiantuo, Z., Jiaxing, Z. & Shuqing, T. (2002). 
Staphylococcus heterogeneously resistant to vancomycin in China and antimicrobial 
activities of imipenem and vancomycin in combination against it. Journal of Clinical 
Microbiology, Vol.40, No.3, pp. 1109-1112. 
Benvenuto, M., Benziger, D.P., Yankelev, S. & Vigliani, G. (2006). Pharmacokinetics and 
tolerability of daptomycin at doses up to 12 milligrams per kilogram of body 
weight once daily in healthy volunteers. Antimicrobial Agents and Chemotherapy, 
Vol.50, No.10, pp. 3245-3249. 
Bouanchaud, D.H. (1992). In-vitro and in-vivo synergic activity and fractional inhibitory 
concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. 
Journal of Antimicrobial Chemotherapy, Vol.30 (Suppl. A), pp. 95–99. 
Bugnon, D., Potel, G., Caillon, J., Baron, D., Drugeon, H.B., Feigel, P., Kergueris, M.F. (1998). 
In vivo simulation of human pharmacokinetics in the rabbit. Bulletin of Mathematical 
Biology, Vol.60, No.3, pp. 545-567. 
Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., Scheld, M., 
Spellberg, B. & Bartlett, J. (2009). Bad bugs, no drugs: no ESKAPE! An update from 
the Infectious Diseases Society of America. Clinical Infectious Diseases, Vol.48, No.1, 
pp. 1-12. 
Carbon, C. (1990). Impact of the antibiotic schedule on efficacy in experimental endocarditis. 
Scandinavian Journal of Infectious Diseases, Suppl. 74, pp. 163–172. 
www.intechopen.com
 
Antibiotics Against Endocarditis – Past, Present and Future (Experimental Data) 
 
119 
Cappelletty, D.M., Kang, S.L., Palmer, S.M. & Rybak, M.J. (1995). Pharmacodynamics of 
ceftazidime administered as continuous infusion or intermittent bolus alone and in 
combination with single daily-dose amikacin against Pseudomonas aeruginosa in an 
in vitro infection model. Antimicrobial Agents and Chemotherapy, Vol.39, No.8, pp. 
1797–1801. 
Cervera, C., Castañeda, X., Pericas, J.M., Del Río, A., de la Maria, C.G., Mestres, C., Falces, 
C., Marco, F., Moreno, A. & Miró, J.M. (2011). Clinical utility of daptomycin in 
infective endocarditis caused by Gram-positive cocci. International Journal of 
Antimicrobial Agents, [Epub ahead of print]. 
Chiang, F.Y. & Climo, M. (2003). Efficacy of linezolid alone or in combination with 
vancomycin for treatment of experimental endocarditis due to methicillin-resistant 
Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, Vol.47, No.9, pp. 3002-
3004. 
Corey, G.R., Wilcox, M.H., Talbot, G.H, Thye, D., Friedland, D., Baculik, T. & CANVAS 1 
investigators. (2010). CANVAS 1: the first Phase III, randomized, double-blind 
study evaluating ceftaroline fosamil for the treatment of patients with complicated 
skin and skin structure infections. Journal of Antimicrobial Chemotherapy, 65 Suppl 4, 
pp. 41-51. 
Cubist Pharmaceuticals. (2003). Cubicin (daptomycin for injection). Cubist Pharmaceuticals, 
Lexington, MA, USA. 
Cunha, B.A., Eisenstein, L.E. & Hamid, N.S. (2006). Pacemaker-induced Staphylococcus aureus 
mitral valve acute bacterial endocarditis complicated by persistent bacteremia from 
a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity. 
Heart Lung, Vol.35, No.3, pp. 207-211. 
Dailey, C.F., Dileto-Fang, C.L., Buchanan, L.V., Oramas-Shirey, M.P., Batts, D.H., Ford, C.W. 
& Gibson, J.K. (2001). Efficacy of linezolid in treatment of experimental 
endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrobial 
Agents and Chemotherapy, Vol.45, No.8, pp. 2304-2308. 
Dailey, C.F., Pagano, P.J., Buchanan, L.V., Paquette, J.A., Haas, J.V. & Gibson, J.K. (2003). 
Efficacy of linezolid plus rifampin in an experimental model of methicillin-
susceptible Staphylococcus aureus endocarditis. Antimicrobial Agents and 
Chemotherapy, Vol.47, No.8, pp. 2655-2658. 
Darville, T. & Yamauchi, T. (1994). The cephalosporin antibiotics. Pediatrics in Review, Vol.15, 
No.2, pp. 54-62. 
Durack, D.T. & Beeson, P.B. (1972). Experimental bacterial endocarditis. I. Colonization of a 
sterile vegetation. British Journal of Experimental Pathology, Vol.53, No.1, pp. 44-49. 
Durack, D.T. & Beeson, P.B. (1972). Experimental bacterial endocarditis. II. Survival of a 
bacterium in endocardial vegetations. British Journal of Experimental Pathology, 
Vol.53, No.1, pp. 50-53. 
Entenza, J.M., Que, Y.A., Vouillamoz, J., Glauser, M.P. & Moreillon P. (2001). Efficacies of 
moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis 
due to methicillin-resistant Staphylococcus aureus expressing various degrees of 
ciprofloxacin resistance. Antimicrobial Agents and Chemotherapy, Vol.45, No.11, pp. 
3076-3083. 
www.intechopen.com
 
Endocarditis 
 
120 
Fowler, V.G. Jr., Scheld, W.M. & Bayer, A.S. (2005). Endocarditis and intravascular 
infections, In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious 
Diseases, Sixth Edition, pp. 975–1022, Philadelphia: Elsevier Churchill Livingstone. 
Garrison, P.K. & Freedman, L.R. (1970). Experimental endocarditis I. Staphylococcal 
endocarditis in rabbits resulting from placement of a polyethylene catheter in the 
right side of the heart. Yale Journal of Biology and Medicine, Vol.42, No.6, pp. 394-410. 
Gonzalez, L.S. 3rd. & Spencer, J.P. (1998). Aminoglycosides: a practical review. American 
Family Physician, Vol.58, No.8, pp. 1811-1820. 
Grohs, P., Kitzis, M.D. & Gutmann, L. (2003). In vitro bactericidal activities of linezolid in 
combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and 
rifampin against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 
Vol.47, No.1, pp. 418-420. 
Heep, M., Rieger, U., Beck, D. & Lehn, N. (2000). Mutations in the beginning of the rpoB 
gene can induce resistance to rifamycins in both Helicobacter pylori and 
Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, Vol.44, No.4, pp. 
1075-1077. 
Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T. & Tenover, F. C. (1997). Methicillin-
resistant Staphylococcus aureus clinical strain with reduced vancomycin 
susceptibility. Journal of Antimicrobial Chemotherapy, Vol.40, No.1, pp. 135–136. 
Jacqueline, C., Batard, E., Perez, L., Boutoille, D., Hamel, A., Caillon, J., Kergueris, M.F., 
Potel, G. & Bugnon, D. (2002). In vivo efficacy of continuous infusion versus 
intermittent dosing of linezolid compared to vancomycin in a methicillin resistant 
Staphylococcus aureus rabbit endocarditis model. Antimicrobial Agents and 
Chemotherapy, Vol.46, No.12, pp. 3706-3712. 
Jacqueline, C., Caillon, J., Le Mabecque, V., Miegeville, A.F., Donnio, P.Y., Bugnon, D. & 
Potel, G. (2003). In vitro activity of linezolid alone and in combination with 
gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus 
aureus by time-kill curve methods. Journal of Antimicrobial Chemotherapy, Vol.51, 
No.4, pp. 857-864. 
Jacqueline, C., Asseray, N., Batard, E., Le Mabecque, V., Kergueris, M.F., Dube, L., Bugnon, 
D., Potel, G. & Caillon, J. (2004). In vivo efficacy of linezolid in combination with 
gentamicin for the treatment of experimental endocarditis due to methicillin-
resistant Staphylococcus aureus. International Journal of Antimicrobial Agents, Vol.24, 
No.4, pp. 393-396. 
Jacqueline, C., Navas, D., Batard, E., Miegeville, A.F., Le Mabecque, V., Kergueris, M.F., 
Bugnon, D., Potel, G. & Caillon, J. (2005). In vitro and in vivo synergistic activities of 
linezolid combined with subinhibitory concentrations of imipenem against 
methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 
Vol.49, No.1, pp. 45-51. 
Jacqueline, C., Caillon, J., Grossi, O., Le Mabecque, V., Miegeville, A.F., Bugnon, D., Batard, 
E. & Potel, G. (2006). In vitro and in vivo assessment of linezolid combined with 
ertapenem: a highly synergistic combination against methicillin-resistant 
Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, Vol.50, No.7, pp. 2547-
2549. 
Jacqueline, C., Caillon, J., Le Mabecque, V., Miègeville, A.F., Hamel, A., Bugnon, D., Ge, J.Y. 
& Potel G. (2007). In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum 
www.intechopen.com
 
Antibiotics Against Endocarditis – Past, Present and Future (Experimental Data) 
 
121 
cephalosporin, compared with linezolid and vancomycin against methicillin-
resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit 
endocarditis model. Antimicrobial Agents and Chemotherapy, Vol.51, No.9, pp. 3397-
3400. 
Jacqueline, C., Caillon, J., Batard, E., Le Mabecque, V., Amador, G., Ge, Y., Biek, D. & Potel, 
G. (2010). Evaluation of the in vivo efficacy of intramuscularly administered 
ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant 
Staphylococcus aureus strain in a rabbit endocarditis model. Journal of Antimicrobial 
Chemotherapy, Vol.65, No.10, pp. 2264-2265. 
Jacqueline, C., Amador, G., Batard, E., Le Mabecque, V., Miègeville, A.F., Biek, D., Caillon, J. 
& Potel G. (2011). Comparison of ceftaroline fosamil, daptomycin and tigecycline in 
an experimental rabbit endocarditis model caused by methicillin-susceptible, 
methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Journal of 
Antimicrobial Chemotherapy, Vol.66, No.4, pp. 863-866.  
Kaatz, G.W., Seo, S.M., Reddy, V.N., Bailey, E.M. & Rybak, M.J. (1990). Daptomycin 
compared with teicoplanin and vancomycin for therapy of experimental 
Staphylococcus aureus endocarditis. Antimicrobial Agents and Chemotherapy, Vol.34, 
No.11, pp. 2081-2085. 
Kaatz, G.W. & Seo, S.M. (1996). In vitro activities of oxazolidinone compounds U100592 and 
U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobial 
Agents and Chemotherapy, vol.40, No.3, pp. 799–801.  
Kennedy, S. & Chambers, H.F. (1989). Daptomycin (LY146032) for prevention and treatment 
of experimental aortic valve endocarditis in rabbits. Antimicrobial Agents and 
Chemotherapy, Vol.33, No.9, pp. 1522-1525. 
LaPlante, K.L. & Woodmansee, S. (2009). Activities of daptomycin and vancomycin alone 
and in combination with rifampin and gentamicin against biofilm-forming 
methicillin-resistant Staphylococcus aureus isolates in an experimental model of 
endocarditis. Antimicrobial Agents and Chemotherapy, Vol.53, no.9, pp. 3880-3886.  
Lefort, A., & Fantin, B. (1999). Rabbit model of bacterial endocarditis, In: Handbook of animal 
models of infection, O. Zak & M.A. Sande, (Ed.), 611-617, ISBN 0-12-775390-7. 
Lim, D. & Strynadka, N.C. (2002). Structural basis for the beta lactam resistance of PBP2a 
from methicillin-resistant Staphylococcus aureus. Nature Structural Biology, Vol.9, 
No.11, pp. 870-876. 
McConeghy, K.W. & LaPlante, K.L. (2010). In vitro activity of tigecycline in combination 
with gentamicin against biofilm-forming Staphylococcus aureus. Diagnostic 
Microbiology and Infectious Disease, Vol.68, No.1, pp. 1–6. 
Malbruny, B.; Canu, A., Bozdogan, B., Zarrouk, V., Fantin, B. & Leclercq, R. (2000). 
Quinupristin/Dalfopristin resistance Mutation Reveals the Involvement of L22 
Ribosomal Protein in Synergy Between Quinupristin and Dalfopristin, Proceedings 
of 40th Interscience Conference Antimicrobial Agents and Chemotherapy, p. 118, Abstr. 
No. 1928, Toronto, Ontario, Canada, September 17-20, 2000. 
Maltezou, H.C. (2009). Metallo-beta-lactamases in Gram-negative bacteria: introducing the 
era of pan-resistance? International Journal of Antimicrobial Agents, Vol.33, No.5, pp. 
405-407. 
Miró, J.M., García-de-la-Mària, C., Armero, Y., Soy, D., Moreno, A., del Río, A., Almela, M., 
Sarasa, M., Mestres, C.A., Gatell, J.M., Jiménez de Anta, M.T., Marco, F. & Hospital 
www.intechopen.com
 
Endocarditis 
 
122 
Clinic Experimental Endocarditis Study Group. (2009). Addition of gentamicin or 
rifampin does not enhance the effectiveness of daptomycin in treatment of 
experimental endocarditis due to methicillin-resistant Staphylococcus aureus. 
Antimicrobial Agents and Chemotherapy, Vol.53, No.10, pp. 4172-4177. 
Miró, J.M., Entenza, J.M., del Río, A., García-de-la-Mària, C., Giddey, M., Armero, Y.,  
Cervera, C., Mestres, C.A., Almela, M., Falces, C., Marco, F., Moreillon, P. & 
Moreno, A. (2009). Daptomycin (DAP) plus Fosfomycin (FOM) is Synergistic 
against Methicillin-Susceptible (MSSA) and Methicillin-Resistant Staphylococcus 
aureus (MRSA) Strains: From Bench to Bedside. Proceedings of 49th Interscience 
Conference Antimicrobial Agents and Chemotherapy, Abstr. No. E-1449, San Francisco, 
CA, USA, September 12-15, 2009. 
Murphy, T.M., Deitz, J.M., Petersen, P.J., Mikels, S.M. & Weiss, W.J. (2000). Therapeutic 
efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental 
endocarditis. Antimicrobial Agents and Chemotherapy, Vol.44, No.11, pp. 3022-3027. 
Nakazawa, H., Kikuchi, Y., Honda, T., Isago, T. & Nozaki, M. (2003). Enhancement of 
antimicrobial effects of various antibiotics against methicillin-resistant 
Staphylococcus aureus (MRSA) by combination with fosfomycin. Journal of Infection 
and Chemotherapy, Vol.9, No.4, pp. 304-309. 
Paterson, D.L. (2006). Clinical experience with recently approved antibiotics. Current Opinion 
in Pharmacology, Vol.6, No.5, pp. 486–490. 
Pavie, J., Lefort, A., Zarrouk, V., Chau, F., Garry, L., Leclercq, R. & Fantin, B. (2002). 
Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in 
experimental endocarditis due to methicillin-resistant Staphylococcus aureus in 
relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type 
antibiotics. Antimicrobial Agents and Chemotherapy, Vol.46, No.9, pp. 3061-3064. 
Rank, D.R., Friedland, H.D. & Laudano, J.B. (2011). Integrated safety summary of FOCUS 1 
and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating 
ceftaroline fosamil for the treatment of patients with community-acquired 
pneumonia. Journal of Antimicrobial Chemother, 66 Suppl 3, pp. 53-59. 
Rello, J. (2005). Pharmacokinetics, pharmacodynamics, safety, and tolerability of tigecycline. 
Journal of Chemotherapy, Vol.17 (Suppl 1), pp. 12–22. 
Rochon-Edouard, S., Pestel-Caron, M., Lemeland, J.F. & Caron, F. (2000). In vitro synergistic 
effects of double and triple combinations of beta-lactams, vancomycin, and 
netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrobial 
Agents and Chemotherapy, Vol.44, No.11, pp. 3055-3060. 
Sahuquillo Arce, J.M., Colombo Gainza, E., Gil Brusola, A., Ortiz Estévez, R., Cantón, E. & 
Gobernado, M. (2006). In vitro activity of linezolid in combination with doxycycline, 
fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-
susceptible Staphylococcus aureus. Revista Espanola de Quimioterapia, Vol.19, No.3, pp. 
252-257. 
Sakoulas, G., Eliopoulos, G.M., Alder, J. & Eliopoulos, C.T. (2003). Efficacy of daptomycin in 
experimental endocarditis due to methicillin-resistant Staphylococcus aureus. 
Antimicrobial Agents and Chemotherapy, Vol.47, No.5, pp. 1714-1718.  
Silverman, J.A., Perlmutter, N.G. & Shapiro, H.M. (2003). Correlation of daptomycin 
bactericidal activity and membrane depolarization in Staphylococcus aureus. 
Antimicrobial Agents and Chemotherapy, Vol.47, No.8, pp. 2538-2544. 
www.intechopen.com
 
Antibiotics Against Endocarditis – Past, Present and Future (Experimental Data) 
 
123 
Singh, S.R., Bacon, A.E. 3rd., Young, D.C. & Couch, K.A. (2009). In vitro 24-hour time-kill 
studies of vancomycin and linezolid in combination versus methicillin-resistant 
Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, Vol.53, No.10, pp. 
4495-4497. 
Slover, C.M., Rodvold, K.A. & Danziger, L.H. (2007). Tigecycline: a novel broad-spectrum 
antimicrobial. Annals of Pharmacotherapy, Vol.41, No.6, pp. 965-972.  
Soriano, A., Jurado, A., Marco, F., Almela, M., Ortega, M. & Mensa, J. (2005). In vitro activity 
of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in 
combination, against Staphylococcus aureus and Staphylococcus epidermidis. Revista 
Espanola de Quimioterapia, Vol.18, No.2, pp. 168-172. 
Spratt, B.G. (1977). Properties of the penicillin binding proteins of Escherichia coli K12. 
European Journal of Biochemistry, Vol.72, No.2, pp. 342-352. 
Tally, F.P. & DeBruin, M.F. (2000). Development of daptomycin for Gram-positive 
infections. Journal of Antimicrobial Chemotherapy, Vol.46, No.4, pp. 523–526. 
Tattevin, P., Basuino, L., Bauer, D., Diep, B.A. & Chambers, H.F. (2010). Ceftobiprole is 
superior to vancomycin, daptomycin, and linezolid for treatment of experimental 
endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. 
Antimicrobial Agents and Chemotherapy, Vol.54, No.2, pp. 610-613.  
The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs 
by 2020. (2010). Infectious Diseases Society of America. Clinical Infectious Diseases, 
Vol.50, No.8, pp. 1081-1083.  
Totsuka, K., Shiseki, M., Kikuchi, K. & Matsui, Y. (1999). Combined effects of vancomycin 
and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro 
and in vivo. Journal of Antimicrobial Chemotherapy, Vol.44, No.4, pp. 455-460. 
Tsaganos, T., Skiadas, I., Koutoukas, P., Adamis, T., Baxevanos, N., Tzepi, I., Pelekanou, A., 
Giamarellos-Bourboulis, E.J., Giamarellou, H. & Kanellakopoulou, K. (2008). 
Efficacy and pharmacodynamics of linezolid, alone and in combination with 
rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus 
endocarditis. Journal of Antimicrobial Chemotherapy, Vol.62, No.2, pp. 381-383. 
The bacterial challenge: time to react, In: European Centre for Disease Prevention and 
Control, European Medicines Agency Joint Technical report, September 2009, 
Available from  
 http://www.emea.europa.eu/pdfs/human/antimicrobial resistance. 
Uete, T. & Matsuo, K. (1995). Synergistic enhancement of in vitro antimicrobial activity of 
imipenem and cefazolin, cephalothin, cefotiam, cefamandole or cefoperazone in 
combination against methicillin-sensitive and -resistant Staphylococcus aureus. 
Japanese Journal of Antibiotics, Vol.48, No.3, pp. 402-408. 
Villegas-Estrada, A., Lee, M., Hesek, D., Vakulenko, S.B. & Mobashery, S. (2008). Co-opting 
the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition 
of PBP 2a by two anti-MRSA beta-lactam antibiotics. Journal of the American 
Chemical Society, Vol.130, No.29, pp. 9212-9213. 
Wilcox, M.H., Corey, G.R., Talbot, G.H., Thye, D., Friedland, D., Baculik, T. & CANVAS 2 
investigators. (2010). CANVAS 2: the second Phase III, randomized, double-blind 
study evaluating ceftaroline fosamil for the treatment of patients with complicated 
skin and skin structure infections. Journal of Antimicrobial Chemotherapy, 65 Suppl 4, 
pp. 53-65. 
www.intechopen.com
 
Endocarditis 
 
124 
Zak, O., Sande, M., & O’Reilly, T. (1999). Introduction: the role of animal models in the 
evaluation of new antibiotics, In: Handbook of animal models of infection, O. Zak & 
M.A. Sande, (Ed.), 611-617, ISBN 0-12-775390-7. 
Zhanel, G.G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., 
Karlowsky, J.A. & Hoban, D.J. (2004). The glycylcyclines: a comparative review 
with the tetracyclines. Drugs, Vol.64, No.1, pp. 63-88. 
Zhanel, G.G., Johanson, C., Embil, J.M., Noreddin, A., Gin, A., Vercaigne, L. & Hoban, D.J. 
(2005). Ertapenem: review of a new carbapenem. Expert Review of Anti-Infective 
Therapy, Vol.3, No.1, pp. 23-39. 
Zyvox [package insert]. (2000). Pharmacia & Upjohn Company, Kalamazoo, MI, USA. 
www.intechopen.com
Endocarditis
Edited by Prof. Francisco Ramón Breijo-Márquez
ISBN 978-953-307-901-1
Hard cover, 152 pages
Publisher InTech
Published online 20, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Endocarditis is a disease that occurs as a result of the inflammation of the endocardium. It is an inflammatory
process located in the inner lining of the cardiac chambers and native or prosthetic valves. It is characterized
by colonization or invasion of the heart valve vegetations composed of platelets forming, fibrin and
microcolonies of microorganisms, and occasionally of inflammatory cells. Other structures may also be
affected, such as the interventricular septum, chordae tendineae, the mural endocardium or even intra-cardiac
implants. The book covers, with scientific rigour, the most prevalent causes and current treatments of
endocarditis, as well as the cases when the organs remote from the heart are affected by this disease.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Cédric Jacqueline, Gilles Amador, Eric Batard, Virginie Le Mabecque, Gilles Potel and Jocelyne Caillon (2012).
Antibiotics Against Endocarditis – Past, Present and Future (Experimental Data), Endocarditis, Prof. Francisco
Ramón Breijo-Márquez (Ed.), ISBN: 978-953-307-901-1, InTech, Available from:
http://www.intechopen.com/books/endocarditis/antibiotics-against-endocarditis-past-present-and-future-
experimental-data-
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
